Pathways and Progress in Improving Drug Delivery Through the Intestinal Mucosa and blood–brain Barriers
- 1 October 2014
- journal article
- review article
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 5 (10) , 1143-1163
Abstract
One of the major hurdles in developing therapeutic agents is the difficulty in delivering drugs through the intestinal mucosa and blood-brain barriers (BBB). The goal here is to describe the genera...Keywords
This publication has 175 references indexed in Scilit:
- Principles of strategic drug delivery to the brain (SDDB): Development of anorectic and orexigenic analogs of leptinPhysiology & Behavior, 2011
- Fibrinogen alters mouse brain endothelial cell layer integrity affecting vascular endothelial cadherinBiochemical and Biophysical Research Communications, 2011
- Enhancing the Intestinal Membrane Permeability of Zanamivir: A Carrier Mediated Prodrug ApproachMolecular Pharmaceutics, 2011
- Toward Eradicating HIV Reservoirs in the Brain: Inhibiting P-Glycoprotein at the Blood–Brain Barrier with Prodrug Abacavir DimersJournal of the American Chemical Society, 2011
- Enhancement of Drug Absorption through the Blood−Brain Barrier and Inhibition of Intercellular Tight Junction Resealing by E-Cadherin PeptidesMolecular Pharmaceutics, 2010
- Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimerBiochemical and Biophysical Research Communications, 2009
- Quantitative modeling of selective lysosomal targeting for drug designEuropean Biophysics Journal, 2008
- Blood–brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horsesJournal of Controlled Release, 2007
- Natural and Synthetic Polymers as Inhibitors of Drug Efflux PumpsPharmaceutical Research, 2007
- Lysosomal Sequestration of Amine-Containing Drugs: Analysis and Therapeutic ImplicationsJournal of Pharmaceutical Sciences, 2007